Kim M. Keeling

3.6k citations

41 papers · 2.6k indexed · h-index 25

Molecular Biology top 5%
Pulmonary and Respiratory Medicine top 5%
Genetics top 10%
Physiology top 10%
Cell Biology top 10%

Co-authors: David M. Bedwell Marina Manuvakhova Joseph X. Ho Daniel C. Carter Ming Du Brian L. Chang Dan Wang Steven M. Rowe
Topics: RNA and protein synthesis mechanisms (13 papers)Advanced biosensing and bioanalysis techniques (9 papers)Cystic Fibrosis Research Advances (9 papers)
Cited by: Molecular Biology Genetics Pulmonary and Respiratory Medicine
Journals: Proceedings of the National Academy of Sciences Journal of Biological Chemistry Nature Communications
Partner nations: United States Israel United Kingdom

In The Last Decade

Kim M. Keeling

40 papers receiving 2.6k citations

Peers

Countries citing papers authored by Kim M. Keeling

Since Specialization

Citations

This map shows the geographic impact of Kim M. Keeling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kim M. Keeling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kim M. Keeling more than expected).

Fields of papers citing papers by Kim M. Keeling

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kim M. Keeling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kim M. Keeling. The network helps show where Kim M. Keeling may publish in the future.

Co-authorship network of co-authors of Kim M. Keeling

This figure shows the co-authorship network connecting the top 25 collaborators of Kim M. Keeling. A scholar is included among the top collaborators of Kim M. Keeling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kim M. Keeling. Kim M. Keeling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Identity, functional consequences, and context effects of amino acids inserted during suppression of CFTR nonsense mutations 2025 ·Journal of Cystic Fibrosis ·(unknown),Jianguo Chen,Lianwu Fu,D. Woodrow Benson,Jens‐Ola Ekström,(unknown),Matthew B. Renfrow,Steven M. Rowe,Kim M. Keeling,David M. Bedwell	0
2	Extended stop codon context predicts nonsense codon readthrough efficiency in human cells 2024 ·Nature Communications ·(unknown),Lianwu Fu,Ming Du,(unknown),Kim M. Keeling,David M. Bedwell,Allan Jacobson	14
3	Discovery of dysregulated circular RNAs in whole blood transcriptomes from cystic fibrosis patients – implication of a role for cellular senescence in cystic fibrosis 2023 ·Journal of Cystic Fibrosis ·(unknown),(unknown),Kim M. Keeling,Yvonne J. K. Edwards	1
4	The synthetic aminoglycoside ELX-02 induces readthrough of G550X-CFTR producing superfunctional protein that can be further enhanced by CFTR modulators 2023 ·American Journal of Physiology-Lung Cellular and Molecular Physiology ·Jianguo Chen,(unknown),Lianwu Fu,Wei Wang,Soheil Aghamohammadzadeh,Hui Wen,Liping Tang,Kim M. Keeling,Emily Falk Libby,David M. Bedwell,Steven M. Rowe	14
5	RNA binding proteins PTBP1 and HNRNPL regulate CFTR mRNA decay 2023 ·Heliyon ·(unknown),Arpit Saxena,(unknown),Viktória Havasi,Lianwu Fu,Kim M. Keeling	2
6	Pharmacological approaches for targeting cystic fibrosis nonsense mutations 2020 ·European Journal of Medicinal Chemistry ·Jyoti Sharma,Kim M. Keeling,Steven M. Rowe	29
7	Mutation-Directed Therapeutics for Neurofibromatosis Type I 2020 ·Molecular Therapy — Nucleic Acids ·André Leier,David M. Bedwell,Ann T. Chen,George Dickson,Kim M. Keeling,Robert A. Kesterson,Bruce R. Korf,(unknown),Ulrich F. Müller,Linda Popplewell,Jiangbing Zhou,Deeann Wallis	22
8	Discovery of Clinically Approved Agents That Promote Suppression of Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations 2016 ·American Journal of Respiratory and Critical Care Medicine ·Venkateshwar Mutyam,Ming Du,(unknown),Kim M. Keeling,E. Lucile White,J. Robert Bostwick,Lynn Rasmussen,Bo Liu,Marina Mazur,Jeong S. Hong,Emily Falk Libby,Feng Liang,(unknown),Martin Mense,Mark J. Suto,David M. Bedwell,Steven M. Rowe	63
9	The nonsense suppression drug PTC124 restored alpha-l-iduronidase activity and reduces glycosaminoglycan accumulation in MPS IH mice carrying the Idua-W402X mutation 2015 ·Molecular Genetics and Metabolism ·David M. Bedwell,Dan Wang,Ellen Welch,Kim M. Keeling	6
10	Long-term nonsense suppression therapy moderates MPS I-H disease progression 2013 ·Molecular Genetics and Metabolism ·(unknown),Yanying Dai,Ming Du,Valery Belakhov,Jeyakumar Kandasamy,Trenton R. Schoeb,Timor Baasov,David M. Bedwell,Kim M. Keeling	42
11	Suppression of premature termination codons as a therapeutic approach 2012 ·Critical Reviews in Biochemistry and Molecular Biology ·Kim M. Keeling,Dan Wang,(unknown),David M. Bedwell	78
12	The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse 2011 ·Molecular Genetics and Metabolism ·Dan Wang,Valery Belakhov,Jeyakumar Kandasamy,Timor Baasov,Su‐Chen Li,Yu‐Teh Li,David M. Bedwell,Kim M. Keeling	59
13	Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases 2011 ·Wiley Interdisciplinary Reviews - RNA ·Kim M. Keeling,David M. Bedwell	71
14	Characterization of an MPS I-H knock-in mouse that carries a nonsense mutation analogous to the human IDUA-W402X mutation 2009 ·Molecular Genetics and Metabolism ·Dan Wang,Charu Shukla,Xiaoli Liu,Trenton R. Schoeb,L. Clarke,David M. Bedwell,Kim M. Keeling	46
15	Distinct eRF3 Requirements Suggest Alternate eRF1 Conformations Mediate Peptide Release during Eukaryotic Translation Termination 2008 ·Molecular Cell ·Hua Fan-Minogue,Ming Du,Andrey V. Pisarev,(unknown),(unknown),Kim M. Keeling,Sunnie R. Thompson,Tatyana V. Pestova,David M. Bedwell	49
16	Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model 2006 ·Journal of Molecular Medicine ·Ming Du,Kim M. Keeling,Liming Fan,Xiaoli Liu,(unknown),Eric J. Sorscher,David M. Bedwell	58
17	Leaky termination at premature stop codons antagonizes nonsense-mediated mRNA decay in S. cerevisiae 2004 ·RNA ·Kim M. Keeling,(unknown),Ming Du,(unknown),Lin Gao,(unknown),David M. Bedwell	137
18	Aminoglycoside suppression of a premature stop mutation in a Cftr–/– mouse carrying a human CFTR-G542X transgene 2002 ·Journal of Molecular Medicine ·Ming Du,(unknown),(unknown),Kim M. Keeling,(unknown),Albert Tousson,Zsuzsa Bebők,Jeffrey A. Whitsett,Chitta R. Dey,William H Colledge,Martin Evans,Eric J. Sorscher,David M. Bedwell	143
19	Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation 2001 ·Human Molecular Genetics ·Kim M. Keeling	126
20	Preliminary Crystallographic Studies of Four Crystal forms of Serum Albumin 1994 ·European Journal of Biochemistry ·Daniel C. Carter,Brian L. Chang,Joseph X. Ho,Kim M. Keeling,(unknown)	232

About Kim M. Keeling

Kim M. Keeling is a scholar working on Molecular Biology, Physiology and Pulmonary and Respiratory Medicine, having authored 41 papers that have together received 2.6k indexed citations. Recurring topics across this work include RNA and protein synthesis mechanisms (13 papers), Advanced biosensing and bioanalysis techniques (9 papers) and Cystic Fibrosis Research Advances (9 papers). The work is most often cited by research in Molecular Biology (2.0k citations), Genetics (167 citations) and Pulmonary and Respiratory Medicine (430 citations). Kim M. Keeling has collaborated with scholars based in United States, Israel and United Kingdom. Frequent co-authors include David M. Bedwell, Marina Manuvakhova, Joseph X. Ho, Daniel C. Carter, Ming Du, Brian L. Chang, Dan Wang, Steven M. Rowe, Venkateshwar Mutyam and Xiaoli Liu. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact